

Medicinal product no longer authorised

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Zulvac 1 Ovis suspension for injection for sheep

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 ml dose contains:

### Active substances:

Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP\*  $\geq 1$

\*Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.

### Adjuvants:

Aluminium hydroxide (Al <sup>3+</sup> )	4 mg
Saponin	0.4 mg

### Excipients:

Thiomersal	0.2 mg
------------	--------

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Suspension for injection. Off-white or pink liquid.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Sheep

### 4.2 Indications for use, specifying the target species

For active immunisation of sheep from 1 and a half months of age for the prevention\* of viraemia caused by Bluetongue Virus (BTV), serotype 1.

\*(Cycling value (Ct)  $\geq 36$  by a validated RT-PCR method, indicating no presence of viral genome).

Onset of immunity: 21 days after completion of the primary vaccination scheme

Duration of immunity: 12 months after completion of the primary vaccination scheme

### 4.3 Contraindications

None.

#### 4.4 Special warnings for each target species

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep. No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies.

#### 4.5 Special precautions for use

##### Special precautions for use in animals

Vaccinate only healthy animals.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

None

#### 4.6 Adverse reactions (frequency and seriousness)

A transient increase in rectal temperature, not exceeding 1.2 °C, may occur very commonly during the 24 hours following vaccination.

Vaccination may be followed very commonly by a local reaction at the injection site. These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 7 days) or of palpable nodules (subcutaneous granuloma, possibly persisting for more than 48 days).

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### 4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy. No data is available on safety in lactating animals. The use in lactating animals is therefore not recommended.

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or national Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV).

#### 4.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### 4.9 Amounts to be administered and administration route

Subcutaneous use.

##### **Primary vaccination:**

Administer one dose of 2 ml according to the following vaccination scheme:

1<sup>st</sup> injection: from 1.5 months of age.

2<sup>nd</sup> injection: after 3 weeks

Apply usual aseptic procedures.

Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection.

The entire content of the bottle should be used immediately after broaching and during the same procedure.

Avoid multiple vial broaching.

In order to avoid accidental contamination of the vaccine during use, it is recommended to use a multi-injection type vaccination system when larger dose presentations are used.

#### **Revaccination:**

Any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

A transient increase in rectal temperature, not exceeding 0.6 °C, may occur during the 24 hours following administration of a two-fold overdose.

Administration of a two-fold overdose may be followed in most animals by a local reaction at the injection site. These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 9 days) or of palpable nodules (subcutaneous granuloma, possibly persisting for more than 63 days).

#### **4.11 Withdrawal period(s)**

Zero days.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Inactivated viral vaccines – Bluetongue virus.

ATC vet code: QI04AA02.

To stimulate active immunity against Bluetongue Virus, serotype 1 in sheep.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Aluminium hydroxide

Saponin

Thiomersal

Potassium chloride

Potassium dihydrogen phosphate

Disodium hydrogen phosphate dodecahydrate

Sodium chloride

Water for injections

## **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

## **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 1 year.

Shelf-life after first opening the immediate packaging: use immediately after broaching.

## **6.4 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).

Protect from light.

Do not freeze.

## **6.5 Nature and composition of immediate packaging**

Cardboard box with one type I glass vial of 20 ml (containing 10 doses) with a chlorobutyl rubber stopper and aluminium cap.

Cardboard box with one type II glass vial of either 100 ml (containing 50 doses) or 240 ml (containing 120 doses) with a chlorobutyl rubber stopper and aluminium cap.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Zoetis Belgium SA  
Rue Laid Burniat 1  
1348 Louvain-la-Neuve  
BELGIUM

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/131/001

EU/2/11/131/005

EU/2/11/131/006

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 05 August 2011

Date of last renewal: 18/04/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

Medicinal product no longer authorised

**ANNEX II**

- A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

Medicinal product no longer authorised

**A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance(s)

Zoetis Manufacturing & Research Spain, S.L.  
Ctra. Camprodón s/n "la Riba"  
17813 Vall de Bianya  
Girona  
SPAIN

Name and address of the manufacturer responsible for batch release

Zoetis Manufacturing & Research Spain, S.L.  
Ctra. Camprodón s/n "la Riba"  
17813 Vall de Bianya  
Girona  
SPAIN

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) The administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) The disease to which the product is intended to confer immunity is largely absent from the territory in question.

The use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of Bluetongue.

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

**C. STATEMENT OF THE MRLs**

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

Medicinal product no longer authorised

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

Medicinal product no longer authorised

**A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Outer carton 1 x 20ml, 1 x 100ml and 1 x 240 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1 Ovis suspension for injection for sheep

**2. STATEMENT OF ACTIVE SUBSTANCES**

Per dose of 2 ml  
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1  
Aluminium hydroxide, saponin and thiomersal.

**3. PHARMACEUTICAL FORM**

Suspension for injection

**4. PACKAGE SIZE**

20 ml (10 doses)  
100 ml (50 doses)  
240 ml (120 doses)

**5. TARGET SPECIES**

Sheep

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Subcutaneous use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s): Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once broached use immediately.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated.  
Protect from light.  
Do not freeze.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium SA  
Rue Laid Burniat 1  
1348 Louvain-la-Neuve  
BELGIUM

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/131/001  
EU/2/11/131/005  
EU/2/11/131/006

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Vial label 100 ml and 240 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1 Ovis suspension for injection for sheep

**2. STATEMENT OF ACTIVE SUBSTANCES**

Per dose of 2 ml  
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1  
Aluminium hydroxide, saponin and thiomersal.

**3. PHARMACEUTICAL FORM**

Suspension for injection

**4. PACKAGE SIZE**

100 ml (50 doses)  
240 ml (120 doses)

**5. TARGET SPECIES**

Sheep

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Subcutaneous use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period(s): Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once broached use immediately.

**11. SPECIAL STORAGE CONDITIONS**

Store and transport refrigerated.

Protect from light.

Do not freeze.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Zoetis Belgium SA  
Rue Laid Burniat 1  
1348 Louvain-la-Neuve  
BELGIUM

**16. MARKETING AUTHORISATION NUMBER(S)**

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Vial label 20 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1 Ovis suspension for injection for sheep

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Per dose of 2 ml  
Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1  
Aluminium hydroxide, saponin and thiomersal.

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

20 ml (10 doses)

**4. ROUTE(S) OF ADMINISTRATION**

SC

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period(s): Zero days.

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once broached use immediately.

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

Medicinal product no longer authorised

**B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**  
**Zulvac 1 Ovis suspension for injection for sheep**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder

Zoetis Belgium SA  
Rue Laid Burniat 1  
1348 Louvain-la-Neuve  
BELGIUM

Manufacturer responsible for batch release:

Zoetis Manufacturing & Research Spain, S.L.  
Ctra. Camprodón s/n "la Riba"  
17813 Vall de Bianya  
Girona  
SPAIN

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zulvac 1 Ovis suspension for injection for sheep

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each 2 ml dose contains:

**Active substance:**

Inactivated Bluetongue Virus, serotype 1, strain BTV-1/ALG2006/01 E1      RP\*  $\geq$  1

\*Relative Potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep.

**Adjuvant:**

Aluminium hydroxide (Al <sup>3+</sup> )	4 mg
Saponin	0.4 mg

**Excipient:**

Thiomersal	0.2 mg
------------	--------

Off-white or pink liquid.

**4. INDICATION(S)**

For active immunisation of sheep from 1 and a half months of age for the prevention\* of viraemia caused by Bluetongue Virus (BTV), serotypes 1.

\*(Cycling value (Ct)  $\geq$  36 by a validated RT-PCR method, indicating no presence of viral genome)

Onset of immunity: 21 days after completion of the primary vaccination scheme

Duration of immunity: 12 months after completion of the primary vaccination scheme

## 5. CONTRAINDICATIONS

None.

## 6. ADVERSE REACTIONS

A transient increase in rectal temperature, not exceeding 1.2 °C, may occur very commonly during the 24 hours following vaccination.

Vaccination may be followed very commonly by a local reaction at the injection site. These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 7 days) or of palpable nodules (subcutaneous granuloma possibly persisting for more than 48 days).

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Sheep

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Subcutaneous use.

### **Primary vaccination:**

Administer one dose of 2 ml according to the following vaccination scheme:

1<sup>st</sup> injection: from 1.5 months of age.

2<sup>nd</sup> injection: after 3 weeks

### **Revaccination:**

Any revaccination scheme should be agreed by the Competent Authority or by the responsible veterinarian, taking into account the local epidemiological situation.

## 9. ADVICE ON CORRECT ADMINISTRATION

In order to avoid accidental contamination of the vaccine during use, it is recommended to use a multi-injection type vaccination system when larger dose presentations are used.

Apply usual aseptic procedures.

Shake gently immediately before use. Avoid bubble formation, as this can be irritating at the site of injection. The entire content of the bottle should be used immediately after broaching and during the same procedure. Avoid multiple vial broaching.

## **10. WITHDRAWAL PERIOD(S)**

Zero days

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.  
Store and transport refrigerated (2 °C – 8 °C).  
Protect from light.  
Do not freeze

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.  
Once broached use immediately.

## **12. SPECIAL WARNING(S)**

Vaccinate only healthy animals.

No information is available on the use of the vaccine in seropositive animals including those with maternally derived antibodies.

If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. The level of efficacy for other species may differ from that observed in sheep.

### Pregnancy:

Can be used during pregnancy.

### Lactation:

No data is available on safety in lactating animals. The use in lactating animals is therefore not recommended.

### Fertility:

The safety and the efficacy of the vaccine have not been established in breeding males. In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/or national Competent Authorities on the current vaccination policies against Bluetongue virus (BTV).

### Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### Overdose (symptoms, emergency procedures, antidotes):

A transient increase in rectal temperature, not exceeding 0.6 °C, may occur during the 24 hours following administration of a two-fold overdose.

Administration of a two-fold overdose may be followed in most animals by a local reaction at the injection site. These reactions take the form in most cases of a general swelling of the injection site (persisting for not more than 9 days) or of palpable nodules (subcutaneous granuloma possibly persisting for more than 63 days).

Incompatibilities:

Do not mix with any other veterinary medicinal product.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>

**15. OTHER INFORMATION**

Pack sizes

Cardboard box with one type I glass vial of 20 ml (containing 10 doses) with a chlorobutyl rubber stopper and aluminium cap.

Cardboard box with one type II glass vial of either 100 ml (containing 50 doses) or 240 ml (containing 120 doses) with a chlorobutyl rubber stopper and aluminium cap.

Not all pack sizes may be marketed.